The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over

Status unconfirmed

Conditions studied: Depression, Mild Cognitive Impairment

In brief

Mild cognitive impairment (MCI) leading to Alzheimer's disease and related disorders (ADRD) represents a significant health and economic burden of the rapidly expanding senior population. The accurate detection and diagnosis of MCI and its common comorbidity, late-life depression (LLD), is essential for prolonging patient quality of life and developing advancements in research and treatment options. The purpose of the proposed program is to refine Miro Health's A.I. to accurately detect, differentiate and diagnose MCI and LLD.

Key facts

Study ID

NCT06011681

Run by

Miro Health

People needed

960

Starts

2023-09-08

Expected to finish

2024-12-31

Last updated by the study team

2024-01-22

Who can join

Age: 60 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• LLD: Age 60 or over; diagnosis of LLD or symptoms consonant with LLD; PHQ-9 score from 15 to 27
• MCI: Age 60 or over; diagnosis of MCI or self-reported insidious onset and continued worsening of cognitive decline; intact activities of daily living
• HC: Age 60 or over

You may not qualify if…

• Age 59 or younger; history of unresolved neurological or psychiatric conditions; current medications known to affect cognition; history of substance abuse; unable to perform activities of daily living; change in employment status due to condition

Where it is running

• Miro Health — Sacramento, California, United States (enrolling)
• Miro Health — Miami, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.